Market Newsdesk

VANCOUVER, BC, April 14, 2021 /PRNewswire/ —  BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the results of a clinical study conducted by ProCare Health Iberia, its EU partner for marketing its gynecological cancer and viral vaccines, which demonstrated the efficacy of Papilocare® in preventing and treating lesions caused by HPV. BioVaxys has right of refusal for US marketing of Papilocare®, the world’s first and only product to prevent and treat HPV-dependent cervical lesions.

HPV (Human papillomavirus infection) infection is one of the most common STI (Sexually Transmitted Infections) worldwide, with around 80% of men and women becoming infected at some point in their life. Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).

Published in the April 2021 Issue of the Journal of Lower Genital Tract Disease (JLGTD), the official journal of the American Society for Colposcopy and Cervical Pathology (ASCCP), the main conclusions from the Paloma Clinical Trial (PALOMA trial, #NCT04002154) include the normalization of cervical lesions in 88% of patients infected with high-risk HPV and a clearance of HPV in 63% of the same group of patients. These results are confirmed by the JLGTD following a detailed review that began after the presentation of the results of the study in June 2019.

The Paloma Clinical which involved nine Spanish hospitals (4 public and 5 private), began in July 2016. It is a multicentre, open, and randomized study conducted in parallel groups and controlled using habitual clinical practice, with the aim of assessing the degree of healing of the cervical mucous in HPV+ women between 30 and 65 years old, with AS-CUS, L-SIL or AG-US smear results and consistent colposcopic image. These results demonstrated normalization of low grade lesions on the cervix (ASCUS/LSIL) in 85% of the patients treated with Papilocare® after 6 months, and the result was even more significant in women infected with high-risk HPV, normalizing lesions in 88% of patients. “The results of the Paloma trial are really good news for HPV patients thanks to the proven efficacy of Papilocare®. These results have been obtained after more than 4 years of research and their publication in an edition the prestigious JLGTD further strengthens their significance,” stated Javier Cortés, MD, Clinical Coordinator of the Paloma study and specialist in Gynecology and Cytology for the international Academy of Cytology (Chicago, USA), member of the Spanish association against Cancer (AECC) and of the European Cervical Cancer Association (ECCA).

As a secondary criterion, the Paloma Clinical Trial demonstrated a 57% increase in the clearance of the high-risk virus, managing to eliminate it in 63% of the patients treated with Papilocare® over 6 months, compared with 40% in the control group. In addition, there is a high level of consistency between the result and the results presented by 3 independent studies carried out by public university hospitals in Spain and Italy, which reported the efficacy of Papilocare® in the clearance of high-risk HPV to be between 50 and 70%.

The results of the Paloma Clinical Trial have also been accepted and presented to gynacologists at the most prestigious European Congresses in the sector, such as the European Federation for Colposcopy (EFC) in Rome in September 2019, the European Society of Gynecology (ESG) in Vienna in October 2019, and the European Society of Gynacological Oncology (ESGO) in Athens in November 2019.

Under the February 2021 agreement between BioVaxys and ProCare, BioVaxys has right of first refusal for US marketing of Procare Health’s vaginal gel product, Papilocare™, the world’s first and only product to prevent and treat HPV-dependent cervical lesions.  Formed in 2012 as a spin-out from Procter & Gamble Pharmaceuticals, Procare Health is a market leader in the women’s health field in the European Union (“EU”), with marketed products including Papilocare™, Libicare™, Palomacare™, Idracare™, Pronolis HD™ and Ovosicare™.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.  The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.

ON BEHALF OF THE BOARD

Signed “James Passin“


James Passin, CEO
+1 646 452 7054

Media Contacts BioVaxys Technology Corp.

Nikita Sachdev

Luna PR
[email protected]

Cautionary Statements Regarding Forward Looking Information

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys’ vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs’ vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biovaxys-announces-final-clinical-trial-results-of-hpv-product-from-eu-partner-procare-health-iberia-published-by-american-society-for-colposcopy-and-cervical-pathology-301268530.html

SOURCE BioVaxys Technology Corp.

SEATTLE, April 14, 2021 /PRNewswire/ — (NASDAQ: RDFN) — One in five Americans (21%) believes the increasing frequency or intensity of natural disasters, extreme temperatures and/or rising sea levels are hurting home values in their area, according to a new survey featured in a report from Redfin (redfin.com), the technology-powered real estate brokerage. A comparable share—23%—expect one or more of these factors to hurt local housing values in the next five years, and 12% think values will be negatively impacted in the next five to 10 years. Just over a third (35%) of Americans believe these factors will never diminish home values where they live.

“Climate change is posing an increasingly large risk to homeowners. As storms, wildfires and rising sea levels render more areas undesirable in the coming years, housing values in those areas will decline. This means a growing number of homeowners will see a major source of wealth—their home equity—wiped away,” said Redfin Chief Economist Daryl Fairweather. “We may also see folks in at-risk areas choose to rent instead of own to avoid getting stuck with devalued properties.”

The breakdowns in the next three sections of this press release focus on the 419 out of 2,000 respondents who indicated that they believe home values in their area are already being negatively impacted by climate change and natural disasters.

Younger Respondents Are More Likely to Say Climate Change Is Affecting Home Values

About a quarter of respondents aged 44 and younger believe home values in their area are already being negatively impacted by the increasing frequency/intensity of natural disasters, extreme temperatures and/or rising sea levels. That compares with 15% of participants aged 45 to 54 and 9% of participants aged 55 and older.

Midwesterners Are Least Likely to Say Climate Change Is Hurting Housing Values

Seventeen percent of respondents living in the Midwest think climate change is negatively affecting housing values in their area, compared with 20% of respondents in the Northeast, 22% in the South and 23% in the West.

While the Midwest is warming up and experiencing greater precipitation in some areas, it hasn’t seen the sudden uptick in devastating natural disasters that other parts of the U.S. have. The West Coast had its most active fire year on record in 2020, with more than five million acres burning across California, Oregon and Washington, and homes in many wildfire-prone zip codes selling for a discount. And in Texas, a massive winter storm in February 2021 left 111 people dead and millions without power.

“Homeowners are still getting their pipes repaired from the freeze. Some are still without water,” said Ashley Vasquez, a Redfin real estate agent in Houston, which is also prone to flooding. “I had one home that was supposed to close a month ago, but the process has been delayed because of the storm. We now have to get the home reinspected and reappraised to assess whether the freeze impacted the value.”

While buyers are concerned about flooding and storms in Texas, many are overlooking these risks because there are so few homes for sale, Vasquez added.

City Dwellers Are Most Likely to Say Climate Change Is Hurting Housing Values

More than a quarter (27%) of city dwellers think local home values are being negatively impacted by the increasing frequency/intensity of natural disasters, extreme temperatures and/or rising sea levels. That compares with 17% of respondents living in suburban areas and 16% living in rural areas.

“Cities tend to skew younger and more liberal, which is likely why they’re home to a larger share of people who are worried about the risks of climate change,” Fairweather said. “Many city leaders have committed to carbon-reduction plans that are much more ambitious than the proposals put forth by federal and state officials.”

Americans Are Spending Thousands of Dollars to Protect Their Homes Against Climate Change

The remainder of this press release focuses on the roughly 1,200 respondents who indicated they own the property they currently live in.

More than half (59%) of surveyed homeowners have invested in making their homes more resilient to at least one climate-related risk, with over a third (36%) spending $5,000 or more.

Extreme temperatures and flooding are the top climate threats the surveyed homeowners are bracing for, with roughly 20% of respondents indicating that they have fortified their properties against one of those risks and/or the other. Next come earthquakes (16%), tornadoes (15%), hurricanes or other major tropical storms (13%) and severe snowstorms (10%).

Americans are fortifying their properties not only to keep themselves and their families safe from the dangers of climate change, but also to protect their home equity, according to Fairweather.

“Some homeowners are finding that in order to preserve the value of their properties, they need to invest in making their homes more resilient to climate change,” Fairweather said. “However, this can be costly and make owning a home even less affordable at a time when housing prices are already soaring.”

Roughly 1 in 3 Homeowners Has Spent at Least $5,000 Fortifying Their Homes Against Climate Threats

More than a third (35%) of surveyed homeowners have invested $5,000 or more to make their properties more resilient to climate risk, while 20% have spent up to $5,000. Of the respondents who have invested in fortifying their homes, the most common amount spent was $5,000 to $9,999.

Ever since the destructive 2017 Tubbs Fire hit northern California, people who stayed in the area have been hard at work strengthening their homes, according to Napa, CA Redfin real estate Christopher Anderson.

“Homeowners are fireproofing their houses and empty lots and removing dead trees and bushes. If they have wood-shake roofs, they’re changing them out for roofs made of concrete or some other material that doesn’t burn. They’re replacing wooden fencing with steel fencing, and wooden decks with stone patios,” Anderson said. “Buyers are also paying more attention than they used to. They’re looking at every property a bit more closely. How close did the fire get? What steps has the seller taken to mitigate fire risk?”

Natural Disaster Insurance Premiums Are on the Rise

About two-thirds (65%) of surveyed homeowners have a home insurance policy covering some type of natural disaster. Flooding is the most common threat for which homeowners possess insurance, with a third (33%) of respondents indicating they have policies to protect against this risk. Next come tornadoes (29%), earthquakes (22%), hurricanes or other major tropical storms (19%) and wildfires (15%).

As weather catastrophes become more frequent, insurance costs have jumped. Almost half (45%) of surveyed homeowners with natural disaster related insurance policies have seen their premiums increase in the last year.

To view the full report, including charts and methodology, please visit: https://www.redfin.com/news/climate-change-impact-home-values-survey/

About Redfin 
Redfin (www.redfin.com) is a technology-powered real estate broker, instant home-buyer (iBuyer), lender, title insurer, and renovations company. We sell homes for more money and charge half the fee. We also run the country’s #1 real-estate brokerage site. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Customers selling a home can take an instant cash offer from Redfin or have our renovations crew fix up their home to sell for top dollar. Since launching in 2006, we’ve saved customers nearly $1 billion in commissions. We serve more than 95 markets across the U.S. and Canada and employ over 4,100 people.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/redfin-survey-1-in-5-americans-believes-climate-change-is-hurting-home-values-in-their-area-301268549.html

SOURCE Redfin

RESTON, Va., April 14, 2021 /PRNewswire/ — Comscore (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today announced an agreement to provide Atlas Obscura, the definitive guide to the world’s hidden wonders, with Comscore’s industry-leading digital audience measurement.

Under the agreement, Atlas Obscura will have access to Comscore’s signature Media Ratings solutions with Plan Metrix Multi-Platform in the US, to better understand audience behavior and media consumption across desktop and mobile devices.

“We are pleased that Atlas Obscura selected Comscore’s digital audience measurement to better understand and articulate to the advertising community both the quantity and the quality of its audience,” said Carol Hinnant, Chief Revenue Officer, Comscore. “We look forward to supporting Atlas Obscura in its efforts to better serve its audience.”

“Comscore’s industry-leading digital audience measurement will help us to more accurately measure our growing audience,” said Warren Webster, CEO of Atlas Obscura. “We are excited to partner with Comscore to gain an even deeper understanding of what resonates with our audience, and continue to provide surprising, wondrous content about the world.”

Atlas Obscura continues to focus on different avenues of changing the world, including creating a global community of explorers, publishing best-in-class journalism, holding extraordinary events all over the country, and leading the world’s most unusual trips to the world’s most remarkable places. Today, they create multimedia content, special events, and creative advertising programs for some of the world’s most exciting brands.

Comscore Media Ratings offers a 360-degree unduplicated view of consumption based on massive, passively collected datasets. Comscore’s innovative lineup of digital media ratings offerings, which includes Media Metrix Multi-Platform, Video Metrix Multi-Platform and Mobile Metrix, allows publishers to evaluate online audiences across desktop and mobile with insights powered by industry-leading census-based digital measurement, including powerful advanced audience segments.

About Comscore
Comscore (NASDAQ: SCOR) is a trusted partner for planning, transacting and evaluating media across platforms. With a data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore allows media buyers and sellers to quantify their multiscreen behavior and make business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry’s emerging, third-party source for reliable and comprehensive cross-platform measurement. To learn more about Comscore, visit www.comscore.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/comscore-signs-new-logo-deal-with-atlas-obscura-for-syndicated-digital-measurement-301268462.html

SOURCE Comscore

SEATTLE, April 14, 2021 /PRNewswire/ — The coronavirus pandemic has upended the housing market, opening up new opportunities for many, pushing some to move back home and causing others to reevaluate how they want their home to look. With vaccines being widely distributed, new Zillow® surveys reveal what’s likely to change and what’s expected to remain when the pandemic ends. 

“As the pandemic subsides and the economy begins to recover, lowered health risks and renewed homeowner financial confidence should bring more sellers to the market,” said Zillow economist Arpita Chakravorty. “That increased inventory would ease buyer competition that has driven prices higher during the pandemic, but expect a steady pace of home value growth to persist into the near future. Mortgage rates have risen some but are still low by historical standards, adding to people’s purchasing power and helping to keep competition for homes revved up.”

Telework is here to stay, which should continue to boost home buying demand…
An overwhelming majority (95%) of economists and real estate experts surveyed by Zillow as part of the Zillow Home Price Expectations (ZHPE) survey say an increased preference to work remotely at least part time is a permanent shift.ⁱ According to Zillow’s Ideal Home Survey, which asked adults to describe their ideal living situation, remote workers are more likely to consider moving because of the pandemic. Of employed people who work remotely at least one day a week, 23% said they are more likely to consider moving because of the pandemic – only 13% of employed people who always work at their employer’s location said the same.ⁱⁱ

With widespread teleworking expected to continue when the pandemic ends, boosted home buying demand thanks to the added flexibility offered by remote work is likely to persist — Zillow economists expect 17.2% more home sales this year than in 2020. 

…but housing location and size preferences may return to pre-pandemic norms
Experts surveyed by Zillow were split on whether housing preference shifts during the pandemic will last. When asked about Americans’ preference for living in the suburbs over urban areas, the same share of ZHPE panelists said the shift was permanent as said the shift was temporary (46%) — 8% said there has been no shift at all. The results were similar when asked whether consumer preference has changed in favor of proximity to smaller cities over larger cities, or larger homes in favor of smaller homes. 

Zillow’s Ideal Home Survey results show no change in the size of Americans’ ideal home since last year. According to the survey, Americans prefer a 2,000-square-foot home with three bedrooms and two bathrooms — the same as when surveyed a year ago.

More homes will come onto the market to help meet demand
In today’s frenzied housing market, buyers are often plucking homes off the market just days after they are listed, thanks in part to technology that’s making home buying and selling faster and easier. The speed at which homes are selling is one factor contributing to low inventory, which has steadily declined during the pandemic and now sits 30% lower than a year ago. 

A majority of ZHPE panelists (53%) expect inventory will begin to grow again this year, likely during the second half of 2021. An increase in existing homes being listed for sale is expected to be the biggest factor in the reversal, with 38% of panelists saying that is the most likely catalyst for inventory growth. 

Previous Zillow research supports this belief. Homeowners representing eight million households say they’re more likely to move and sell their home as a result of the pandemic, and widespread coronavirus vaccine distribution will make homeowners in 14 million households feel comfortable moving who don’t necessarily feel that way now. 

“As the economy continues to recover, more potential sellers will enter the market as they gain confidence in their employment,” said Samer Kuraishi, president and founder at The ONE Street Company in Washington, D.C. “It’s been tough on homeowners who want to sell but might have lost their job, or cannot work remotely. Increased employment stability will only raise confidence and push people off the sidelines. While we have optimism about April and the summer, our work with clients will remain the same: arm, educate, and empower them to learn the market and understand the road ahead.”

Home prices will continue their climb
Strong competition for available homes pushed up prices last year — the typical home appreciated by more than $20,000 in 2020. Even with an expectation for more inventory to help meet buyer demand, ZHPE panelists on average expect home prices to grow 6.2% in 2021 — a full two percentage points higher than when they were surveyed in Q4 2020 — and several panelists call for double-digit price growth this year. 

“This is the most bullish near-term outlook for home prices we’ve seen from our experts since the early stages of the post-bust recovery, and the panel’s five-year average annual home price forecast has never been more optimistic,” said Terry Loebs, founder of Pulsenomics. “In the wake of last year’s heady home equity gains, these new projections indicate that the aggregate value of homes across the country will increase by another $2 trillion in 2021. This is great news for existing homeowners, but even with a robust economic rebound in the coming months affordability will likely remain a challenge for many aspirational renters looking to move into homeownership this year.”

Buyers will continue to want digital tools that make home shopping easier

“Zillow Surfing” has surged during the pandemic as home shoppers and daydreamers use Zillow as a new form of escapism. Real estate technology, like Zillow’s 3D Home tours, are making home shopping easier and faster and can give home shoppers an experience similar to an in-person tour from their couch hundreds or thousands of miles away. Nearly 60% of millennials say they would be at least somewhat comfortable making an offer on a home without touring in person if they’ve viewed a virtual tour, and almost 40% even say they would be comfortable buying a home online.

Demand for these tools is expected to continue once the pandemic ends. One in three respondents to a Zillow survey say they would prefer taking a virtual or video home tour instead of touring a home in person after the pandemic, a departure from traditional shopping behavior. And 79% of Americans say they’d like to view a 3D virtual tour while shopping for a home. 

The results achieved from listings using these technologies support the preferences stated by consumers in the survey. From March 2020 through February 2021, for-sale home listings on Zillow with a Zillow 3D Home tour were viewed 65% more and favorited (saved) 75% more than for-sale home listings without a Zillow 3D Home tour.ⁱⁱⁱ Listings with a Zillow 3D Home tour sold, on average, 10% faster than listings without.^iv

Buyers gravitate toward waterfront living
Zillow’s Ideal Home Survey found a notable increase in people who say their dream location is near the water. More people say their ideal home would be on or near a beach (21%, up from 17% in 2020) or a lake (16%, up from 12%) than last year.

The kitchen cements itself as the most important room in a home
A large kitchen is the home feature the most people say they couldn’t live without, according to Zillow’s Ideal Home Survey. Seventy percent of those surveyed said a large kitchen is extremely or very important, edging out a large ensuite bathroom (68%), walk-in closet (63%) and a patio or deck (62%) as the must-have feature in their ideal home. 

It’s even more indispensable for those who say they’re more likely to move because of the pandemic — 78% of them say a large kitchen is extremely or very important, more than those who are less likely to move.

Buyers are often willing to pay a premium for the kitchen of their dreams. Among the 10 features most often mentioned in listings that sold for more than expected during the pandemic in 2020, six are kitchen-related. Steam ovens were the most-coveted feature of the year, associated with a 4.9% sale premium. 

Only 25% said a pool is extremely or very important in their ideal home — perhaps because they’re dreaming of swims in the ocean or lake instead. 

About
 Zillow Group
Zillow Group, Inc. (NASDAQ: Z and ZG) is reimagining real estate to make it easier to unlock life’s next chapter. 

As the most-visited real estate website in the United States, Zillow® and its affiliates offer customers an on-demand experience for selling, buying, renting or financing with transparency and nearly seamless end-to-end service. Zillow Offers® buys and sells homes directly in dozens of markets across the country, allowing sellers control over their timeline. Zillow Home Loans™, our affiliate lender, provides our customers with an easy option to get pre-approved and secure financing for their next home purchase. Zillow recently launched Zillow Homes, Inc., a licensed brokerage entity, to streamline Zillow Offers transactions.  

Zillow Group’s brands, affiliates and subsidiaries include Zillow®, Zillow Offers®, Zillow Premier Agent®, Zillow Home Loans™, Zillow Closing Services™, Zillow Homes, Inc., Trulia®, Out East®, StreetEasy® and HotPads®. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). 

About Pulsenomics
Pulsenomics LLC (www.pulsenomics.com) is an independent research firm that specializes in data analytics, opinion research, new product and index development for institutional clients in the financial and real estate arenas. Pulsenomics also designs and manages expert surveys and consumer polls to identify trends and expectations that are relevant to effective business management and monitoring economic health. Pulsenomics LLC is the author of The Home Price Expectations Survey™, The U.S. Housing Confidence Survey, The Housing Confidence Index, and The Transaction Sentiment Index. Pulsenomics® , The Housing Confidence Index™, The Transaction Sentiment Index™, and The Housing Confidence Survey™ are trademarks of Pulsenomics LLC.

ⁱ This edition of the Zillow Home Price Expectations Survey surveyed 110 experts between February 15, 2021 and March 1, 2021. The survey was conducted by Pulsenomics LLC on behalf of Zillow, Inc. The Zillow Home Price Expectations Survey and any related materials are available through Zillow and Pulsenomics.
ⁱⁱ Zillow Group Population Science collected a nationally representative sample of more than 1,000 Americans. Fielded between March 1 and March 7, 2021, the survey asked participants questions about their ideal home, including details like size, layout, and location. In previous years, HarrisPoll fielded this survey for Zillow Group; to maintain year-over-year comparability, the ZG Population Science survey used the same questions developed by HarrisPoll. The 2021 survey also asked participants new questions about remote work and their likelihood of moving because of the pandemic.
ⁱⁱⁱ Daily average.
^iv Based on data collected Dec 2019 – May 2020.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/what-to-expect-in-the-housing-market-after-the-pandemic-301268452.html

SOURCE Zillow

FREMONT, Calif. and WALTHAM, Mass., April 14, 2021 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia. The achievement of this development milestone triggers a $5 million payment to Ardelyx.

The Phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum phosphorus in patients who switch from one or more phosphate binders to tenapanor for hyperphosphatemia in Japan.  

“As we approach our April 29 PDUFA date for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis and prepare for potential commercialization in the U.S., we are pleased to see the significant progress made by our partner Kyowa Kirin,” said Mike Raab, president and chief executive officer of Ardelyx. “We are thrilled to have key strategic partners like Kyowa Kirin, along with our partners in Canada and China, to support development of, and once approved, patient access to, tenapanor globally.”

Under the terms of the license agreement for tenapanor with Kyowa Kirin, which was signed in 2017 Ardelyx received a $30 million upfront payment and is eligible to receive up to $55.0 million in total development milestones and 8.5 billion yen in commercialization milestones. Ardelyx is also eligible to receive high-teen royalties on sales throughout the term of the agreement. Kyowa Kirin has been granted the exclusive rights to develop, market and commercialize tenapanor for cardiorenal diseases and conditions associated with them, including hyperphosphatemia, in Japan.

About Tenapanor for Hyperphosphatemia
Tenapanor, discovered and developed by Ardelyx, is a first-in-class, proprietary, oral medicine for which an NDA is under review by the FDA for the control of serum phosphorus in adult patients with CKD on dialysis. Tenapanor has a unique mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). This results in a conformational change of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate at the primary pathway of phosphate absorption. Ardelyx is conducting NORMALIZE, an ongoing extension study of the PHREEDOM Phase 3 monotherapy study, which is designed to evaluate the ability of tenapanor, as monotherapy or in combination with sevelamer, to achieve serum phosphorus levels in the normal range (2.5 – 4.5 mg/dL) in patients with chronic kidney disease (CKD) on dialysis. Planned analyses have demonstrated that the use of tenapanor as a foundational approach, as monotherapy or in combination with sevelamer carbonate, produces a significant phosphorus-lowering effect. After ~ 20 months of treatment with tenapanor alone or with low doses of sevelamer, patients exhibited a mean serum phosphorus reduction of 2.33 mg/dL, from a mean baseline phosphorus of 7.27 mg/dL at the beginning of the PHREEDOM trial to a mean of 4.94 mg/dL.

About Ardelyx, Inc.
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company’s NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA^® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for tenapanor in controlling serum phosphorus in chronic kidney disease patients on dialysis as monotherapy or in combination with Sevelamer carbonate. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelia’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties associated with the drug development, regulatory approval and commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelia’s business in general, please refer to Ardelia’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2021, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical-studies-of-tenapanor-for-hyperphosphatemia-in-japan-301268341.html

SOURCE Ardelyx

VANCOUVER, BC, April 14, 2021 /PRNewswire/ – District Metals Corp. (TSXV: DMX) (FRA: DFPP); (“District” or the “Company”) is pleased to provide an update on the maiden drill program currently being executed at the high grade polymetallic Tomtebo Property located in the Bergslagen Mining District in south-central Sweden. 

District commenced a 5,000 m drill program at the Tomtebo Property on March 15, 2021 (see news release here), targeting numerous high grade polymetallic zones at the historic Tomtebo Mine. To date, a total of 1,377 m has been drilled in seven holes. Drill core samples from the first three holes have been sent to ALS Geochemistry in Malå, Sweden for preparation and analysis, with results expected by late-May. 

All drilling thus far has been concentrated at the Steffenbergs and Oscarsgruvan zones as follow up, infill, and step outs from historical drilling that returned high grade polymetallic mineralization over significant widths. 

Appointment of Key Technical Advisor

Rodney Allen, BSc, PhD of Volcanic Resources has been appointed as Technical Advisor to the Company. Dr. Allen was Manager, Geology Research and Development for the Boliden Group in Sweden for ten years. Prior to that position, he studied several polymetallic ore deposits in Sweden. His geological interpretations were instrumental in the discovery of new ore bodies at Garpenberg and Renström.

Garrett Ainsworth, CEO of District, commented: “We are very pleased with the progression of our maiden drill program at Tomtebo. Our technical team and drill crew in the field are firing on all cylinders, which has resulted in optimized production from the drill rig with best practices being carried out with regards to health, safety, and the environment. We are very excited to receive assay results from our first three drill holes next month.

The official appointment of Rodney Allen as a Technical Advisor for District Metals is a natural fit. Rodney is an important addition to the technical team given his depth of highly relevant experience at Boliden’s Garpenberg Mine, and elsewhere in Sweden. Between Rodney and our Country Manager, Hein Raat, the Company is fully equipped to unlock the potential at Tomtebo.”     

The Company has also granted a total of 200,000 stock options to employees and consultants of the Company, in accordance with the provisions of its stock option plan. Each stock option is exercisable at $0.40 per common share (being the closing price of the Company’s common shares on April 13, 2021, the grant date). All stock options have a term of five years and vest on the grant date.

Technical Information

All scientific and technical information in this news release has been prepared by, or approved by Garrett Ainsworth, PGeo, President and CEO of the Company.  Mr. Ainsworth is a qualified person for the purposes of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

Mr. Ainsworth has not verified any of the information regarding any of the properties or projects referred to herein other than the Tomtebo Property. Mineralization on any other properties referred to herein is not necessarily indicative of mineralization on the Tomtebo Property.

The drill results reported in this news release are historical in nature. District has not undertaken any independent investigation of the sampling nor has it independently analyzed the results of the historical exploration work in order to verify the results. The author of the NI 43-101 Technical Report on the Tomtebo Property has completed historical data verification and validation work, and has concluded that the historical drill results at the Tomtebo Mine do not conform to the presently accepted industry standards. District considers these historical drill results relevant as the Company will use this data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes, however, the Company’s future exploration work will include verification of the data through drilling.

About District Metals Corp.

District Metals Corp. is led by industry professionals with a track record of success in the mining industry. The Company’s mandate is to seek out, explore, and develop prospective mineral properties through a disciplined science-based approach to create shareholder value and benefit other stakeholders.

The advanced exploration stage Tomtebo Property is located in the Bergslagen Mining District of south-central Sweden is the Company’s main focus. Tomtebo comprises 5,144 ha, and is situated between the historic Falun Mine and Boliden’s Garpenberg Mine that are located 25 km to the northwest and southeast, respectively. Two historic polymetallic mines and numerous polymetallic showings are located on the Tomtebo Property along an approximate 17 km trend that exhibits similar geology, structure, alteration and VMS/SedEx style mineralization as other significant mines within the district. Mineralization that is open at depth and along strike at the historic mines on the Tomtebo Property has not been followed up on, and modern systematic exploration has never been conducted on the Property.

On Behalf of the Board of Directors
“Garrett Ainsworth“
President and Chief Executive Officer

(604) 288-4430

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information.

This news release contains certain statements that may be considered “forward-looking information” with respect to the Company within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and any similar expressions. In addition, any statements that refer to expectations, predictions, indications, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.  Forward-looking statements in this news release relating to the Company include, among other things, statements relating to the Company’s planned exploration activities, including its drill target strategy and next steps for the Tomtebo Property; the company’s interpretations and expectations about the mineralization of the Tomtebo mine; the Company’s belief that the numerous gravity high anomalies identified at the historic Tomtebo Mine provide immense expansion potential; the Company’s belief that the modeled gravity high anomalies at the historic Tomtebo Mine could correspond with polymetallic and/or iron sulphide mineralization, or a mafic unit; and the Company’s belief that the gravity high anomaly located one kilometer to the northeast of the Tomtebo Mine represents a potential grassroots discovery opportunity with a modeled tonnage that compares with the historic production tonnage from the historic Falun Mine.

These statements and other forward-looking information are based on opinions, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate and reasonable in the circumstances, as of the date of this news release, including, without limitation, assumptions about the reliability of historical data and the accuracy of publicly reported information regarding past and historic mines in the Bergslagen district; the Company’s ability to raise sufficient capital to fund planned exploration activities, maintain corporate capacity and satisfy the  exploration expenditure requirements required by the definitive purchase agreement between the Company and the vendor of the Tomtebo Property (the “Definitive Purchase Agreement“) by the times specified therein; and stability in financial and capital markets. 

Forward-looking information is necessarily based on a number of  opinions, assumptions and estimates that, while considered reasonable by the Company as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: the reliability of historic data regarding the Tomtebo Property; the Company’s ability to raise sufficient capital to finance planned exploration (including incurring prescribed exploration expenditures required by the Definitive Purchase Agreement, failing which the Tomtebo Property will be forfeited without any repayment of the purchase price); the Company’s limited operating history; the Company’s negative operating cash flow and dependence on third-party financing; the uncertainty of additional funding; the uncertainties associated with early stage exploration activities including general economic, market and business conditions, the regulatory process, failure to obtain necessary permits and approvals, technical issues, potential delays, unexpected events and management’s capacity to execute and implement its future plans; the Company’s ability to identify any mineral resources and mineral reserves; the substantial expenditures required to establish mineral reserves through drilling and the estimation of mineral reserves or mineral resources; the Company’s dependence on one material project, the Tomtebo Property; the uncertainty of estimates used to calculated mineralization figures; changes in governmental regulations; compliance with applicable laws and regulations; competition for future resource acquisitions and skilled industry personnel; reliance on key personnel; title matters; conflicts of interest; environmental laws and regulations and associated risks, including climate change legislation; land reclamation requirements; changes in government policies; volatility of the Company’s share price; the unlikelihood that shareholders will receive dividends from the Company; potential future acquisitions and joint ventures; infrastructure risks; fluctuations in demand for, and prices of gold, silver and copper; fluctuations in foreign currency exchange rates; legal proceedings and the enforceability of judgments; going concern risk; risks related to the Company’s information technology systems and cyber-security risks; and risk related to the outbreak of epidemics or pandemics or other health crises, including the recent outbreak of COVID-19. For additional information regarding these risks, please see the Company’s Annual Information Form, under the heading “Risk Factors”, which is available at www.sedar.com. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company. These factors and assumptions, however, should be considered carefully. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking statements or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Also, many of such factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. All scientific and technical information contained in this news release has been prepared by or reviewed and approved by Garrett Ainsworth, PGeo, President and CEO of the Company. Mr. Ainsworth is a qualified person for the purposes of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

View original content to download multimedia:http://www.prnewswire.com/news-releases/district-provides-drilling-update-from-the-tomtebo-property-and-appointment-of-key-technical-advisor-301268292.html

SOURCE District Metals Corp.

SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.

CP is a group of disorders that affect a person’s ability to move and maintain balance and posture. Many of the common symptoms of CP are similar to other neurotransmitter disorders, such as Aromatic L-amino Acid Decarboxylase (AADC) deficiency, resulting in potential misdiagnosis. The program, PTC Pinpoint Direct™-CP Spectrum, is an innovative, genetic testing program which includes expert genetic counseling at no charge for eligible patients.

“An umbrella diagnosis of a neurotransmitter disorder, such as cerebral palsy, can be extremely frustrating, especially for patients and caregivers who spend years with unexplained and underlying symptoms,” said Kylie O’Keefe, Senior Vice President, Global Commercial and Corporate Strategy, PTC Therapeutics. “Up to one-third of cerebral palsy cases are driven by a genetic disorder, and some of those conditions may have transformative treatments currently available. We are excited to launch this new extension of our existing program, PTC PINPOINT, to further eliminate the barriers of genetic testing for rare diseases.”

PTC Pinpoint Direct™-CP Spectrum will be available at no charge to patients of all ages in the United States who have symptoms consistent with, or a diagnosis of, CP without evidence of brain injury.  Testing with PTC Pinpoint Direct™-CP Spectrum may help uncover a genetic cause of the symptoms and determine the right plan for the patient’s care, including new and emerging treatment options. PTC Pinpoint Direct™-CP Spectrum may also eliminate unnecessary treatments or medications that may cause complications.

The program is sponsored by PTC Therapeutics and is the first collaboration between PTC, Genome Medical for expert genetic counseling and administration, and Invitae for industry-leading genetic testing. Caregivers and patients may initiate the testing process from PTC Pinpoint Direct online and receive information on eligibility requirements. Additional details can be found at www.PTCPinpointDirect.com.

About aromatic L-amino acid decarboxylase (AADC) deficiency
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare genetic condition caused by a mutation in the dopa decarboxylase (DDC) gene, resulting in a lack of functioning AADC enzyme, which is responsible for the final step in the synthesis of key neurotransmitters dopamine and serotonin.2

AADC deficiency results in delays or failure to reach developmental milestones such as head control, sitting, standing, walking, or talking, low muscle tone (also known as muscular hypotonia), severe, seizure-like episodes involving involuntary eye movement (also known as oculogyric crises), autonomic abnormalities, and the need for life-long care.2 Given this neurologically devastating illness, patients with severe AADC deficiency have a high risk of death during childhood. There are currently no approved therapies that address the underlying cause.

About Invitae
Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.

About Genome Medical
Genome Medical is a digital health company that is transforming the delivery of genetic and genomics care through telehealth and digital infrastructure innovations. It operates as an independent virtual medical practice, with on-demand genetic expertise, testing recommendations and patient navigation platforms that accelerate the delivery of genomic insights as a service. To learn more, visit genomemedical.com and follow @GenomeMed.

About PTC
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and on Twitter at @PTCBio.

References:

1. Jaeken et al. Disorders of Neurotransmission. Inborn Metabolic Diseases. 2006.
2. Wassenberg et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017; 12:12.

 

For More Information:

Investors:

Kylie O’Keefe

+1 (908) 300-0691
[email protected]

Media:

Jane Baj

+1 (908) 912-9167
[email protected]

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, PTC’s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance”, “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those factors discussed in the “Risk Factors” section of PTC’s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-launches-the-ptc-pinpoint-direct-program-for-patient-initiated-genetic-testing-301268537.html

SOURCE PTC Therapeutics, Inc.

VANCOUVER, BC, April 14, 2021 /PRNewswire/ — Nickel Rock Resources Inc. (the “Company”) (TSX-V: NICL) (OTCQB: NIKLF) is pleased to announce that a recent staking program has increased the size of the Nickel 100 Claim Group situated in the Mitchell Range, approximately 130 km northwest of Fort St. James in Central British Columbia. The claim group is underlain by silicified and serpentinized ultramafics, a similar package of rocks as the Decar Deposit, and include numerous prospective nickel and chromium showings occurring over a linear distance of 31 km. 

This enlarged land package is, in part, contiguous with FPX Nickel’s (TSXV: FPX) Klow Project where mineralization consists of a central coarse-grained nickel-iron alloy (awaruite) target that is enveloped by a halo of finer-grained mineralization. The coarse-grained target measured 1,000 metres long. In 2012, FPX reported that work on the Klow Project included a ground-based magnetic geophysical survey, the results of which were used to assist in locating drill holes as part of an initial phase of exploration drilling.

Forestry roads and helicopters provide primary access to the property. A BC Rail Line is located approximately 12 km to the south.

About the Nickel 100 Group

Mineral Occurrences

• The claims of the Nickel 100 Group (part of the “Nickel Project”) cover 18 of 18 BC MINFILE chromite occurrences, some of which are reported to be mineralized with nickel, platinum/palladium group and other rare, highly valuable elements.

History

• Nickel-cobalt mineralization has not been well-explored, but the presence of awaruite has been documented. Geologist, Ms. Ursula Mowat completed a preliminary field work program over the area of the Nickel 100 claim group in 2004, and confirmed the presence of elevated nickel, cobalt and chromium values in rocks and stream sediments. Ms. Mowat is the recipient of the 2015 H.H. “Spud” Huestis Award for Excellence in Prospecting and Mineral Exploration granted by the Association of Mineral Exploration in British Columbia (“AME BC“).  AME BC is both a large and successful industry association representing the mineral exploration industry in British Columbia.

About the Hard Nickel Group

• The Hard Nickel Group (part of the “Nickel Project”) consists of four non-contiguous mineral claims groups held by Nickel Rock Resources Inc. through three separate agreements. The exploration stage project is in the Takla Lake area of central British Columbia, partially adjacent to FPX Nickel Corp.’s Decar Nickel Project.
• The Decar Nickel Project is an advanced project targeting awaruite, a nickel-iron alloy mineral, hosted by serpentinized ultramafic intrusive rocks of the Trembleur Ultramafic Unit within the Permian to Triassic age Cache Creek Complex.
• All the claim groups of the Nickel Project are partially underlain by variably serpentinized ultramafic intrusive rocks of the Trembleur Ultramafic Unit. Metallic mineralization discovered to date on the project includes nickel, cobalt, and chromium, and some of the nickel mineralization occurs as the nickel-iron alloy awaruite, and as sulphide minerals including heazlewoodite, bravoite and siegenite.
• The principal target on the project is nickel occurring as awaruite, but at the exploration stage all other styles of mineralization should be considered.
• Systematic, ground-based exploration work began within the area of the claims now covered by the Nickel Project under the direction of Ms. Ursula Mowat, P.Geo. in 1987, continuing intermittently until 2012. This work established the presence of elevated nickel, cobalt and chromium values in rocks, soils, and stream sediments.
• The area of the claim groups of the Nickel Project were included in Geoscience BC’s QUEST and QUEST-West projects, including multiparameter regional geophysical surveys, and regional stream sediment reanalyzes and data compilations between 2008 and 2009.
• R. Britten’s technical paper “Regional Metallogeny and Genesis of a New Deposit Type – Disseminated Awaruite (Ni3Fe) Mineralization Hosted in the Cache Creek Terrane published in 2017 in Economic Geology should be utilized as an interim mineral deposit model or profile for the Nickel Project.
• The Nickel Project is worthy of phased, systematic exploration programs designed and implemented to delineate areas with known or high probability metallic nickel mineralization, and to discover new areas of similar mineralization.

Proposed 2021 Exploration Program

A 2021 proposed work program consists of trenching, surface exploration diamond drilling, camp construction, and exploration activities to support drilling and trenching such as soil sampling, rock sampling, prospecting, and geological mapping. The Company proposes a 12-man camp to be built in a cirque on the north slope of the un-named mountain west of and adjacent to Mount Sydney Williams and will be built next to a sub-alpine lake at the headwaters of Van Decar Creek. The location of camp was selected based on past exploration camps at this location and is suitable for exploration support and the camp will be used to accommodate field personnel and is accessible by helicopter.

Nickel Rock’s Lithium Project

Clayton Valley Project, Silver Peak, Nevada

The Company is exploring for lithium clays and brines within its project area of 118 claims covering over 930 hectares (2,300 acres). The property stretches in a northwest direction from the evaporation ponds of Albemarle Corporation (NYSE: ALB). It has been widely reported that Albemarle is planning to double its lithium production by 2025 by committing between US$30 million and US$50 million in additional investment on the property. In 2021, Albemarle plans to commence exploration of clay and evaluate technology that could accelerate the viability of lithium production from clay resources in the region. 

Qualified Person

Jacques Houle, P.Eng., a qualified person as defined by NI43 – 101, is responsible for the technical information contained in this release. Readers are cautioned that the information in this press release regarding the property of FPX Nickel Corp is not necessarily indicative of the mineralization on the property of interest.

About Nickel Rock Resources Inc. 

The Company is a Canadian-based mineral exploration company active in the exploration for nickel-iron alloy in British Columbia and lithium in Nevada. Nickel Rock Resources Inc. is a Canadian based exploration company whose primary listing is on the TSX Venture Exchange. The Company’s maintains a focus on exploration for high value battery metals required for the electric vehicle (EV) market.  (http://www.nickelrockresources.com/)

On Behalf of the Board of Directors

“Robert Setter“

Robert Setter, President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which include, but are not limited to, comments that involve future events and conditions, which are subject to various risks and uncertainties. Except for statements of historical facts, comments that address resource potential, upcoming work programs, geological interpretations, receipt and security of mineral property titles, availability of funds, and others are forward-looking. Forward-looking statements are not guarantees of future performance and actual results may vary materially from those statements. General business conditions are factors that could cause actual results to vary materially from forward-looking statements.

Nickel Rock Resources Inc.
1220 – 789 West Pender Street
Vancouver, BC, Canada V6C 1H2
604- 428-5690
www.nickelrockresources.com   
[email protected] 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nickel-rock-completes-expansion-of-the-nickel-100-claim-group-near-the-decar-nickel-district-of-fpx-nickel-corp-301268425.html

SOURCE Nickel Rock Resources Inc.

BERWYN, Pa., April 14, 2021 /PRNewswire/ —  AMETEK, Inc. (NYSE: AME) will issue its first quarter 2021 earnings release before the market opens on Tuesday, May 4, 2021.

AMETEK will webcast its first quarter 2021 investor conference call on Tuesday, May 4, 2021, beginning at 8:30 AM ET. The live audio webcast can be accessed by clicking on the Events & Presentations link in the “Investors” section of www.ametek.com. A replay of the call will also be archived on the website and will be available until the next quarterly earnings call. 

Corporate Profile:
AMETEK is a leading global manufacturer of electronic instruments and electromechanical devices with annual sales in 2020 of more than $4.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies – Operational Excellence, New Product Development, Global and Market Expansion, and Strategic Acquisitions – with a disciplined focus on cash generation and capital deployment. AMETEK’s objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. The common stock of AMETEK is a component of the S&P 500.

Contact:
AMETEK, Inc.
Kevin Coleman
Vice President, Investor Relations
1100 Cassatt Road
Berwyn, Pennsylvania 19312
[email protected]
Phone: 610.889.5247

View original content:http://www.prnewswire.com/news-releases/ametek-announces-first-quarter-2021-earnings-call-and-webcasted-investor-conference-call-information-301268279.html

SOURCE AMETEK, Inc.

WASHINGTON, April 14, 2021 /PRNewswire/ — UATP announced today it is broadening its work with PayPal to include Pay in 4 as an option for airfare purchased via UATP Merchant Airlines. With Pay in 4 from PayPal, customers pay for their purchases in four interest-free payments and merchants get paid up front.*

“The buy now, pay later (BNPL) product has become increasingly popular for travelers,” said Ralph Kaiser, president and CEO, UATP.  “The PayPal-UATP relationship has 15 years of demonstrated success and we expect that to continue with Pay in 4.”

Pay in 4 is an interest-free, short-term pay later solution that can be used for qualifying purchases of $30–$600. Customers who select Pay in 4 pay for their purchase in four payments every two weeks over six weeks, with the first payment due at purchase. Now that PayPal offers its Pay in 4 checkouts on airfare, travelers can tap into it via the merchant’s UATP connection – spreading out their purchase with clear, predictable payments. 

For more information, visit UATP.com

*About Pay in 4: Consumer late fee may apply for missed payments and varies by consumer’s state of residency. Loans to California residents are made or arranged pursuant to a California Finance Lenders Law License. PayPal, Inc. is a Georgia Installment Lender Licensee, NMLS # 910457. 

ABOUT UATP
UATP is a global payment network owned and operated by the world’s airlines and accepted by thousands of merchants for air, rail and travel agency payments. UATP connects airlines to Alternative Forms of Payment which can expand reach and generate incremental sales globally. UATP offers easy-to-use data tools, DataStream^® and DataMine^®, which provide comprehensive account details to Issuers and corporate travel buyers for accurate travel management.

Accepted as a form of payment for corporate business travel worldwide by airlines, travel agencies and Amtrak^®; UATP accounts are issued by: Aeromexico; Air Canada (TSE:AC); Air China; Air New Zealand (ANZFF.PK); Air Niugini; Air Serbia; American Airlines (NASDAQ: AAL); APG Airlines; Austrian Airlines; BCD Travel; China Eastern Airlines (NYSE: CEA); Delta Air Lines (NYSE: DAL); EL AL Israel Airlines; Etihad Airways; Fareportal; Frontier Airlines; GOL Linhas aereas inteligentes S.A. (NYSE: GOL and Bovespa: GOLL4); Hahn Air; High Point; Japan Airlines (9201:JP); JetBlue Airways; Qantas Airways (QUBSF.PK); Shandong Airlines;  Sichuan Airlines; Southwest Airlines; Sun Country Airlines; TUIfly GmbH; Turkish Airlines (ISE:THYAO); United Airlines (NASDAQ: UAL) and WestJet.

AirPlus International issues the UATP-based Company Account for Lufthansa German Airlines.

Contact:
UATP Corporate Communications
Wendy Ward, [email protected]  
+1 202 250 4665 

View original content to download multimedia:http://www.prnewswire.com/news-releases/uatp-to-offer-pay-in-4-with-paypal-for-airfare-purchases-across-its-airline-partners-301267937.html

SOURCE Universal Air Travel Plan, Inc. (UATP)